Signati Medical

Executive Summary

Signati Medical is a private medical device company headquartered in San Diego, focused on transforming vasectomy with its bipolar Sealed Vasectomy Procedure (SVP). The company aims to address the lack of innovation in vasectomy over the past two decades by offering a procedure that is faster, safer, and more comfortable for patients. The procedure is designed to be performed in a urologist's office and completed in minutes, potentially increasing patient acceptance and access. Signati Medical's technology represents a significant advancement in men's health, targeting a large and growing market. As a private company with limited public information, the venture remains in early stages with unproven commercial traction. Despite the promising technology, Signati Medical faces typical medtech challenges including regulatory hurdles, clinical validation, and market adoption. The company has not disclosed funding, valuation, or revenue, suggesting it may be pre-revenue and dependent on external capital. Success will hinge on achieving FDA clearance, demonstrating clinical superiority, and forging distribution partnerships. The competitive landscape for vasectomy devices is relatively sparse, offering a first-mover advantage but also requiring significant education and adoption efforts. Overall, the opportunity is compelling but carries substantial execution risk.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) submission50% success
• Q3 2026Clinical trial enrollment completion60% success
• Q2 2026Series A funding round40% success